Superworth

Inovio Pharmaceuticals EPS INO

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
−$1.16
Latest quarter, Q2 FY26
−$0.07
Fiscal year 2025
−$1.93

Inovio Pharmaceuticals' earnings per share was −$1.16 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.07.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.93n/a
FY2024−$4.04n/a
FY2023−$6.12n/a
FY2022−$14.28n/a
FY2021−$17.40n/a
FY2020−$13.44n/a
FY2019−$14.76n/a
FY2018−$12.60n/a
FY2017−$12.96n/a
FY2016−$12.12n/a
FY2015−$5.40n/a
FY2014−$7.56n/a
FY2013−$16.92n/a
FY2012−$6.72n/a
FY2011−$5.76n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.07n/a−$1.16
Q1 FY26−$0.28n/a−$1.70
Q4 FY25$0.06n/a−$1.93
Q3 FY25−$0.87n/a−$2.64
Q2 FY25−$0.61n/a−$2.66
Q1 FY25−$0.51n/a−$3.24
Q4 FY24−$0.65n/a−$4.04
Q3 FY24−$0.89n/a−$4.49
Q2 FY24−$1.19n/a−$5.12
Q1 FY24−$1.31n/a−$5.54
Q4 FY23−$1.10n/a−$6.12
Q3 FY23−$1.52n/a−$7.66

Against its peers

Companies in Drug Manufacturers - General nearest Inovio Pharmaceuticals' size, closest first, today.

CompanyEPS, 12 monthsGrowth
INOInovio Pharmaceuticals−$1.16
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Inovio Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.